A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Bladder cancer surveillance often requires invasive procedures like cystoscopy.
• Novel noninvasive biomarkers are needed for effective patient monitoring.
• CellDetect is a histochemical stain differentiating malignant and benign cells based on metabolic signatures.

Purpose of the Study:

• To validate the performance of the CellDetect assay in a multicenter, blinded study.
• To assess CellDetect's sensitivity and specificity in identifying urothelial carcinoma (UCC).
• To compare CellDetect with standard urine cytology and BTA stat for bladder cancer detection.

Main Methods:

• A multicenter, blinded study involving 217 patients with a history of bladder cancer.
• Urine specimens were stained with CellDetect and interpreted by blinded cytologists.
• Results were compared against cystoscopy and/or biopsy as the reference standard.

Main Results:

• CellDetect demonstrated an overall sensitivity of 84% and specificity of 84%.
• Sensitivity for low-grade, nonmuscle-invasive bladder cancer was 78%, outperforming BTA stat (54%) and standard cytology (33%).
• Patients with positive CellDetect results and negative reference standards had a significantly higher risk of developing UCC.

Conclusions:

• CellDetect is a validated urine-based assay for identifying UCC in patients with a history of bladder cancer.
• The assay maintains high sensitivity across all cancer grades and stages without compromising specificity.
• Further research is needed to evaluate CellDetect's role in routine bladder cancer surveillance as a noninvasive alternative to cystoscopy.